Bayat, S., et al| 2021 | GPS driving: a digital biomarker for preclinical Alzheimer disease| Alz Res Therapy| 13 | 115. https://doi.org/10.1186/s13195-021-00852-1
A study of drivers over the age 65 tracked them using GPS to investigate the driving performance and driving space of older adults with and without preclinical Alzheimer’s Disease (AD ) . From the GPS tracking the researchers the top five most important features consisted of two features describing driving performance (average jerk and over speeding) and three features describing driving space (total number of night trips, radius of gyration, and number of trips shorter than 1 mile.) The researchers’ findings suggest that driving may serve as an effective and accurate digital biomarker for identifying preclinical AD among older adults
Alzheimer disease (AD) is the most common cause of dementia. Preclinical AD is the period during which early AD brain changes are present but cognitive symptoms have not yet manifest. The presence of AD brain changes can be ascertained by molecular biomarkers obtained via imaging and lumbar puncture. However, the use of these methods is limited by cost, acceptability, and availability. The preclinical stage of AD may have a subtle functional signature, which can impact complex behaviours such as driving. The objective of the present study was to evaluate the ability of in-vehicle GPS data loggers to distinguish cognitively normal older drivers with preclinical AD from those without preclinical AD using machine learning methods.
We followed naturalistic driving in cognitively normal older drivers for 1 year with a commercial in-vehicle GPS data logger. The cohort included n equal to 64 individuals with and n equal to 75 without preclinical AD, as determined by cerebrospinal fluid biomarkers. Four Random Forest (RF) models were trained to detect preclinical AD. RF Gini index was used to identify the strongest predictors of preclinical AD.
The F1 score of the RF models for identifying preclinical AD was 0.85 using APOE ε4 status and age only, 0.82 using GPS-based driving indicators only, 0.88 using age and driving indicators, and 0.91 using age, APOE ε4 status, and driving. The area under the receiver operating curve for the final model was 0.96.
The findings suggest that GPS driving may serve as an effective and accurate digital biomarker for identifying preclinical AD among older adults.
GPS driving: a digital biomarker for preclinical Alzheimer disease [primary paper]
BBC News also highlight these research findings in the article: How your driving might reveal early signs of Alzheimer’s
via BBC News | US approves first new Alzheimer’s drug in 20 years
The first new treatment for Alzheimer’s disease for nearly 20 years has been approved by regulators in the United States, paving the way for its use in the UK.
Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms.
At least 100,000 people in the UK with a mild form of the disease could be suitable for the drug.
But approval from the UK regulator could take more than a year.
Charities have welcomed the news (Source: BBC News)
Full story from BBC News
Wang, Y-Y et al | 2021 | The Effect of Cognitive Intervention on Cognitive Function in Older Adults With Alzheimer’s Disease: A Systematic Review and Meta-Analysis | Neuropsychology Review 2021 | April 24 |
Cognitive intervention includes cognitive stimulation, cognitive training, and cognitive rehabilitation. This systematic review was performed to re-assess the efficacy of cognitive intervention for the patients with Alzheimer’s disease (AD). Twenty studies (2012 participants) were eventually included. For global cognitive function, the combined mean difference (MD) in eight studies was 1.67 for the short term. The pooled standardized mean difference (SMD) of six RCTs was 1.61 for the medium term. The pooled SMD of seven studies was 0.79 for the long term. For depression, the pooled SMD of two trials was -0.48 for the short term. Cognitive training may show obvious improvements in global cognitive function whether after short, medium, or long-term interventions and in depression after short term intervention. However, the positive effect of the intervention on general cognitive function or depression did not seem to persist after intervention ended. There is still a lack of reliable and consistent conclusions relevant to the effect of cognitive stimulation and cognitive rehabilitation on observed outcomes, cognitive training for memory or other non-cognitive outcomes. PROSPERO registration number: CRD42019121768.The Effect of Cognitive Intervention on Cognitive Function in Older Adults With Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Abstract available from the journal Neuropsychology Review 2021
Rotherham NHS staff? Why not request a copy of the article from the Library
Alzheimer’s Research UK | July 2020 | Progressing towards a tau blood test for Alzheimer’s disease
- Four new studies presented at the Alzheimer’s Association International Conference (AAIC) and two published papers show that levels of tau, a hallmark protein of Alzheimer’s disease, in the blood could be used to detect the disease
- The research focuses on a specific form of tau, p-tau217
- The new data suggests blood levels of p-tau217 can predict the development of Alzheimer’s disease before symptoms appear, track well with levels of tau in the brain and distinguish Alzheimer’s from other diseases that cause dementia
Researchers from both the US and Europe have presented data that indicates levels of a specific form of tau, one of the hallmark proteins of Alzheimer’s disease, can be measured in blood to detect the disease, even before symptoms appear.
Full details of the studies are available from Alzheimer’s Research UK
In the news:
The Independent ‘Exciting’ results on blood test that could detect Alzheimer’s 20 years before memory falter
BBC News Alzheimer’s: ‘Promising’ blood test for early stage of disease
The Telegraph Flu jab may reduce risk of dementia by a fifth, study finds
Researchers have uncovered part of the explanation for why poor sleep is linked to Alzheimer’s disease. | via ScienceDaily
Poor sleep is a hallmark of Alzheimer’s disease. People with the disease tend to wake up tired, and their nights become even less refreshing as memory loss and other symptoms worsen. But how and why restless nights are linked to Alzheimer’s disease is not fully understood.
Now, researchers at Washington University School of Medicine in St. Louis may have uncovered part of the explanation. They found that older people who have less slow-wave sleep — the deep sleep needed to consolidate memories and wake up feeling refreshed — have higher levels of the brain protein tau. Elevated tau is a sign of Alzheimer’s disease and has been linked to brain damage and cognitive decline.
The findings, published in Science Translational Medicine, suggest that poor-quality sleep in later life could be a red flag for deteriorating brain health.
Full story at ScienceDaily
Link to research: Lucey BP, et al. | Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease | Science Translational Medicine | Jan. 9, 2019
See also: Lack of deep sleep and more day time naps could be early sign of Alzheimer’s, study suggests | The Independent
University of Exeter | November 2018 | Alzheimer’s Society to fund Exeter research into brain inflammation
The Alzheimer’s Society is funding research at the University of Exeter as part of a three-year project which will investigate the role that infections have in driving inflammation in the brain of someone with Alzheimer’s disease. The researchers have received a £361,000 grant to enable their research in this area.
Professor Katie Lunnon, Associate Professor of Epigenetics at the University of Exeter Medical School said: “Systemic infections, like pneumonia or a urinary tract infection, are associated with the onset of dementia, a faster rate of cognitive decline, and the increased risk of death in those living with dementia. Understanding the role of inflammation in Alzheimer’s disease is of utmost importance if we are to treat the disease more effectively.” (Source: University of Exeter)
The full story is available from University of Exeter
Sleep requirements change throughout life. As part of normal aging, sleep generally becomes briefer and fragmented, with older people often having multiple naps throughout the day. In this article, Osman Shabir explains that this may not be the pattern of sleep seen in patients with Alzheimer’s disease and other neurodegenerative conditions, however. | via News Medical
Most patients with Alzheimer’s develop sleep problems which worsen as the disease progresses. Some common sleep disturbances seen in patients with Alzheimer’s are:
- Loss of the ability to stay asleep, despite being able to get to sleep
- Increased sleep latency (duration required to get to sleep is longer)
- Increased agitation before bedtime and throughout the night
- Disorientation upon waking up (in the night, or in the morning)
- Sleepy during the day, whilst being alert during the night (circadian abnormalities)
- Periodic limb movement (PLM) is worsened in around 50% of Alzheimer’s patients
- Shorter duration of both slow-wave-sleep (SWS) and rapid-eye movement sleep (REM) despite the total number of sleep cycles remaining unchanged
The article notes however that not all studies have shown a significant correlation between sleep disruption and Alzheimer’s disease, either in the pre-clinical stage or after symptoms develop. Therefore, not all Alzheimer’s patients suffer from sleep problems, and likewise, not all people suffering from sleep issues in older age necessarily have Alzheimer’s. However, it is now increasingly accepted that sleep loss may indeed be an important risk factor and symptom of Alzheimer’s disease. Whether sleep loss contributes to Alzheimer’s progression, or whether Alzheimer’s causes sleep problems, is yet to be determined.
Full article: Alzheimer’s Disease and sleep disruption | News Medical
A new computer model maps how misshapen proteins associated with Alzheimer’s and Parkinson’s diseases spread throughout the brain. The work could aid in finding ways to diagnose and treat these neurodegenerative disorders | via Stanford News
For the first time, scientists have developed a computer simulation of how clumps of defective proteins in neurodegenerative diseases like Alzheimer’s spread through the brain, much of the time in stealth mode, over as long as 30 years.
“We hope the ability to model neurodegenerative disorders will inspire better diagnostic tests and, ultimately, treatments to slow down their effects,” said Stanford mechanical engineer Ellen Kuhl, who describes the work in Physical Review Letters.
Full article at Stanford News
UCL | October 2018 | First patient trial will test new approach to treating Alzheimer’s disease
A new clinical trial that is using a novel approach to the progression of Alzheimer’s disease is being led by UCL researchers in London. The trial known as DESPIAD will study whether a drug that removes a protein from the brain can help patients with Alzheimer’s disease.
“After a long struggle for funding of our different approach to possible treatment of Alzheimer’s disease, it is exciting to finally have started the DESPIAD trial, which has been made possible by the NIHR and the Wolfson Foundation. We now hope it can proceed as swiftly as possible,” said Professor Sir Mark Pepys (UCL Medicine), who led the development of the new drug.
Almost all medications tested have been focussed on the abnormal fibrous protein accumulations, known as amyloid plaques and neurofibrillary tangles, which are always present in the brain in Alzheimer’s disease. The drugs have aimed at removing or preventing the formation of these abnormal deposits (Source: UCL).
For the full details of the trial, read the press release from UCL
NIHR | Landmark new trial starts for novel Alzheimer’s disease treatment
Kuźma, Elżbieta et al.| 2018| Stroke and dementia risk: A systematic review and meta-analysis| Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association , Vol. 0 , Issue 0 | https://doi.org/10.1016/j.jalz.2018.06.3061
A new systematic review and meta- analysis is the first to conduct a meta-analysis of the relationship between stroke and all-cause dementia risk. This systematic review and meta-analysis provides evidence that stroke is a strong independent risk factor for dementia. The review is published in Alzheimer & Dementia: The Journal of the Alzheimer’s Association.
Stroke is an established risk factor for all-cause dementia, though meta-analyses are needed to quantify this risk.
We searched Medline, PsycINFO, and Embase for studies assessing prevalent or incident stroke versus a no-stroke comparison group and the risk of all-cause dementia. Random effects meta-analysis was used to pool adjusted estimates across studies, and meta-regression was used to investigate potential effect modifiers.
We identified 36 studies of prevalent stroke (1.9 million participants) and 12 studies of incident stroke (1.3 million participants). For prevalent stroke, the pooled hazard ratio for all-cause dementia was 1.69. Study characteristics did not modify these associations, with the exception of sex which explained 50.2% of between-study heterogeneity for prevalent stroke.
Stroke is a strong, independent, and potentially modifiable risk factor for all-cause dementia.
Read the full article at the Alzheimer’s & Dementia